Jan Novák

Active 1994–2026

Also published as
Jan Novak
263
Papers
28,433
Citations
93
h-index
225
i10-index

Citations

Citations per year for Jan Novák1994: 4 citations1995: 2 citations1996: 3 citations1997: 1 citations1998: 3 citations1999: 4 citations2000: 9 citations2001: 10 citations2002: 7 citations2003: 17 citations2004: 32 citations2005: 37 citations2006: 29 citations2007: 76 citations2008: 119 citations2009: 131 citations2010: 155 citations2011: 177 citations2012: 273 citations2013: 194 citations2014: 290 citations2015: 262 citations2016: 285 citations2017: 282 citations2018: 341 citations2019: 941 citations2020: 1,159 citations2021: 1,494 citations2022: 986 citations2023: 1,063 citations2024: 1,525 citations2025: 773 citations2026: 107 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,170 citing papers, 19.6% of this breakdownChina: 1,277 citing papers, 11.5% of this breakdownGermany: 882 citing papers, 8% of this breakdownUnited Kingdom: 829 citing papers, 7.5% of this breakdownFrance: 468 citing papers, 4.2% of this breakdownItaly: 463 citing papers, 4.2% of this breakdownCanada: 377 citing papers, 3.4% of this breakdownNetherlands: 328 citing papers, 3% of this breakdownAustralia: 319 citing papers, 2.9% of this breakdownJapan: 309 citing papers, 2.8% of this breakdownSpain: 291 citing papers, 2.6% of this breakdownSwitzerland: 282 citing papers, 2.6% of this breakdown
0%19.6%Other 27.7%

Fields

  • Medicine41.8%
  • Biochemistry, Genetics and Molecular Biology23.2%
  • Computer Science15.4%
  • Immunology and Microbiology6.3%
  • Chemistry3.2%
  • Engineering2.9%
  • Other7.2%

Topics

  • Renal Diseases and Glomerulopathies5.1%
  • Computer Graphics and Visualization Techniques3.9%
  • Glycosylation and Glycoproteins Research3.7%
  • Advanced Vision and Imaging3%
  • Chronic Kidney Disease and Diabetes2.1%
  • Acute Myeloid Leukemia Research1.9%
  • Other80.3%

Coauthors

All papers

Open in search
  1. Glycosylation in health and disease

    Authors: , , , - Nature Reviews Nephrology 2019 cited by 2,114

  2. Real-time Neural Radiance Caching for Path Tracing

    Authors: , , , - ACM Transactions on Graphics, ACM Trans. Graph. 2021 cited by 160

  3. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2020 cited by 756

  4. Kernel-predicting convolutional networks for denoising Monte Carlo renderings

    Authors: , , , , , , , , - ACM Transactions on Graphics, ACM Trans. Graph. 2017 cited by 319

  5. The Pathophysiology of IgA Nephropathy

    Authors: , , , , , , , , , , - Journal of the American Society of Nephrology 2011 cited by 876

  6. IgA nephropathy

    Authors: , , , , , , - Nature Reviews Disease Primers 2016 cited by 508

  7. Denoising with kernel prediction and asymmetric loss functions

    Authors: , , , , , , , - ACM Transactions on Graphics, ACM Trans. Graph. 2018 cited by 180

  8. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction

    Authors: , , , , , , , , , , , , , , , , , - Journal of the American Society of Nephrology 2016 cited by 288

  9. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gianluca Caridi, Monica Bodria, Francesca Lugani, Landino Allegri, Marco Delsante, Mariarosa Maiorana, Andrea Magnano, Giovanni M. Frascà, Emanuela Boer, Giuliano Boscutti, Claudio Ponticelli, Renzo Mignani, Carmelita Marcantoni, Domenico Di Landro, Domenico Santoro, Antonello Pani, Rosaria Polci, Sandro Feriozzi, Silvana Chicca, Marco Galliani, Maddalena Gigante, Loreto Gesualdo, Pasquale Zamboli, Giovanni Giorgio Battaglia, Maurizio Garozzo, Dita Maixnerová, Vladimı́r Tesař, Frank Eitner, Thomas Rauen, Jürgen Floege, Tibor Kovács, Judit Nagy, Krzysztof Mucha, Leszek Pączek, Marcin Zaniew, Małgorzata Mizerska-Wasiak, Maria Roszkowska–Blaim, Krzysztof Pawlaczyk, Daniel P. Gale, Jonathan Barratt, Lise Thibaudin, F. Berthoux, Guillaume Canaud, Anne Boland, Marie Metzger, Ulf Panzer, Hitoshi Suzuki, Shin Goto, Ichiei Narita, Yaşar Çalışkan, Jingyuan Xie, Ping Hou, Nan Chen, Hong Zhang, Robert Wyatt, Jan Novák, Bruce A. Julian, John Feehally, Bénédicte Stengel, Daniele Cusi, Richard P. Lifton, Ali G. Gharavi - Nature Genetics 2014 cited by 626

  10. Practical Path Guiding for Efficient Light-Transport Simulation

    Authors: , , - Computer Graphics Forum, Comput. Graph. Forum 2017 cited by 122

  11. Abiotic Stress in Crop Production

    Authors: , , , , - International Journal of Molecular Sciences 2023 cited by 334

  12. Mice overexpressing BAFF develop a commensal flora–dependent, IgA-associated nephropathy

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2011 cited by 278

  13. Muscle-specific microRNAs in skeletal muscle development

    Authors: , , - Developmental Biology 2015 cited by 494

  14. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2018 cited by 548

  15. Monte Carlo Methods for Volumetric Light Transport Simulation

    Authors: , , , - Computer Graphics Forum, Comput. Graph. Forum 2018 cited by 134

  16. Recursive Control Variates for Inverse Rendering

    Authors: , , , , , - ACM Transactions on Graphics, ACM Trans. Graph. 2023 cited by 30

  17. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels

    Authors: , , , , , , , , , , , , - Kidney International 2007 cited by 417

  18. Current Understanding of the Role of Complement in IgA Nephropathy

    Authors: , , , , , , - Journal of the American Society of Nephrology 2015 cited by 338

  19. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression

    Authors: , , , , , , , , - Kidney International 2012 cited by 249

  20. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

    Authors: , , , , , , , , , , , , , , , - Haematologica 2022 cited by 130

  21. Residual ratio tracking for estimating attenuation in participating media

    Authors: , , - ACM Transactions on Graphics, ACM Trans. Graph. 2014 cited by 93

  22. Neural Importance Sampling

    Authors: , , , , - ACM Transactions on Graphics, ACM Trans. Graph. 2019 cited by 77

  23. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy

    Authors: , , , , , , - Frontiers in Immunology 2019 cited by 167

  24. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA nephropathy

    Authors: , , , , , , - Kidney International 2019 cited by 161